Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: bone mineral density

Glucocorticoid Use May Result in Loss of Bone Mineral Density

Michele B. Kaufman, PharmD, BCGP  |  March 8, 2023

Adami et al. examined the fracture risk associated with glucocorticoid treatment in women with inflammatory rheumatic musculoskeletal diseases, finding that low-dose glucocorticoid use may result in significant bone mineral density loss in patients who are not on anti-osteoporotic drugs.

Filed under:ACR ConvergenceDrug Updates Tagged with:ACR Convergence 2022bone lossbone mineral density (BMD)fracture riskGlucocorticoidsinflammatory musculoskeletal disease

Denosumab vs. Zoledronate: An Analysis of Treatments for Low Bone Mineral Density in Patients with HIV

Michele B. Kaufman, PharmD, BCGP  |  May 9, 2022

In a small study of men with low bone mineral density (BDM) living with HIV and taking anti-retroviral therapy, both zoledronate or denosumab were well tolerated and effective for bone mineral density of the lumbar spine and femoral neck.

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bone mineral density (BMD)denosumabHIVOsteoporosisosteoporosis treatmentszoledronate

Improving Bone Mineral Density: Risedronate vs. Denosumab

Michele B. Kaufman, PharmD, BCGP  |  March 2, 2022

Treatment with denosumab for patients with RA and glucocorticoid-induced osteoporosis led to greater increases in bone mineral density of the lumbar spine and hips of patients than treatment with risedronate.

Filed under:ACR ConvergenceConditionsDrug UpdatesMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:ACR Convergence 2021bone mineral density (BMD)denosumabGlucocorticoidsOsteoporosisrisedronate

Bone Mineral Density Most Important Determinant of Fracture Risk

Reuters Staff  |  September 7, 2018

NEW YORK (Reuters Health)—In what is believed to be the largest study investigating genetic and clinical determinants of osteoporotic fracture risk, only a genetic predisposition to low bone mineral density (BMD) had a potential causal role to play. “Notably, genetic predisposition to lower levels of vitamin D and estimated calcium intake from dairy sources were…

Filed under:ConditionsOsteoarthritis and Bone DisordersRheumatoid Arthritis Tagged with:bone mineral density (BMD)fracture riskfracture risk determinantFracturesOsteoporosis

Romosozumab Improves Bone Mineral Density in Men with Osteoporosis

Anne Harding  |  July 7, 2018

NEW YORK (Reuters Health)—Romosozumab improves bone mineral density (BMD) in men with osteoporosis, but safety concerns are holding up its approval in the U.S. Up to 2 million men in the U.S. have osteoporosis, and up to 13 million have osteopenia, researchers note in a report online June 20 in The Journal of Clinical Endocrinology…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bone mineral density (BMD)FracturesmenOsteoporosisromosozumab

Proton Pump Inhibitor Use May Be Linked to Bone Mineral Density

Michele B. Kaufman, PharmD, BCGP  |  October 19, 2016

The use of proton pump inhibitors may lead to changes in bone mineral density and an increased risk of developing osteoporosis…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bone mineral density (BMD)denosumabGlucocorticoid-Induced OsteoporosisGlucocorticoidsOsteoporosisproton pump inhibitor (PPI)

Glucocorticoid Found to Increase Bone Mineral Density in Mouse Study

Lara C. Pullen, PhD  |  December 19, 2014

Recent research suggests the lymphocyte-suppressive effect of dexamethasone may underlie the glucocorticoid’s effect on building trabecular bone density

Filed under:ConditionsOsteoarthritis and Bone DisordersResearch Rheum Tagged with:boneGlucocorticoidsOsteoporosisResearch

To the Bone: Experts Discuss Developments in Osteoporosis Care

Thomas R. Collins  |  January 29, 2024

During ACR Convergence 2023, experts discussed developments in the treatment and diagnosis of osteoporosis, addressing risks of treatment discontinuation, the use of bone turnover markers in patient assessment and vitamin D.

Filed under:ACR ConvergenceConditionsOsteoarthritis and Bone Disorders Tagged with:ACR Convergence 2023denosumabOsteoporosisVitamin D

Denosumab Has Edge on Alendronate for Steroid-Induced Bone Loss

Matthew Phelan  |  March 10, 2021

NEW YORK (Reuters Health)—Long-term glucocorticoid users see greater gains in spine bone-mineral density when treated with the monoclonal antibody denosumab vs. oral alendronate, a small clinical trial shows. The drug also proved superior at lowering bone-turnover markers at 12 months, researchers in Hong Kong report in Bone.1 “Denosumab may be considered as an alternative first-line…

Filed under:Drug Updates Tagged with:alendronatebone lossbone mineral density (BMD)denosumabGlucocorticoids

Therapeutic Exercise for Bone Health

Mary Beth Nierengarten  |  December 17, 2020

ACR CONVERGENCE 2020—Attention to bone health in people at risk of developing, or who already have, osteoporosis is essential to reduce their increased risk for fragility fractures. Major risk factors for osteoporosis include being female, white, of small frame and having a family history of osteoporosis, as well as having secondary causes of osteoporosis, such…

Filed under:ACR ConvergenceConditionsMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:ACR Convergence 2020boneExerciseexercise therapyOsteoporosispostmenopausalpremenopauseWomen

  • 1
  • 2
  • 3
  • …
  • 16
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences